B. Braun Medical said the FDA has approved Piperacillin and Tazobactam, one of the most used injectable antibiotics in the U.S., for use in its DUPLEX Drug Delivery System. The company said it will begin moving toward a full launch.
Piperacillin and Tazobactam in the DUPLEX Drug Delivery System is a ready-to-activate, two-compartment container that keeps pre-measured medication and diluent separate until the provider is ready to administer at the bedside by folding, squeezing and shaking to reconstitute. This system reduces overall process time by nearly four minutes per dose and shows substantial labor time savings compared to both the Baxter Mini-Bag Plus Container System and traditional compounding, offering healthcare professionals a new and efficient way to administer this critical antibiotic combination.
DUPLEX is also designed to reduce contamination risks and medication errors. The closed-system design helps protect potency and ensures the diluent cannot be delivered without the drug. Furthermore, DUPLEX decreases the likelihood of medication errors by 54% compared to traditional compounding methods based on fewer process steps. DUPLEX requires no thawing and can be stored at room temperature or in automated dispensing cabinets.
Piperacillin and Tazobactam in the DUPLEX Drug Delivery System will mark the second DUPLEX Drug launch in 2025 (in addition to Cefazolin 3g) and is one of many planned injectable drugs B. Braun will launch in the U.S. in the next several years to expand its portfolio and help meet the needs of patients for medications in high demand.
